News Quantified

BCDA – biocardia, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort [Yahoo! Finance]

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results [Yahoo! Finance]

-5.7%

IN-LINE

-0.4%

MISS

0.5%

MISS

Form 8-K BioCardia, Inc. For: May 01

Form 4 BioCardia, Inc. For: Apr 19 Filed by: Altman Peter

Form DEF 14A BioCardia, Inc. For: May 20

Form SC 13D/A BioCardia, Inc. Filed by: Frost Gamma Investments Trust

Form PRE 14A BioCardia, Inc. For: May 20

Top News Gainers

4/28 BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart 52.7%

10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%

7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%

1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%

7/30 Form CERT BioCardia, Inc. 13.7%

4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%

5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%

3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%

10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%

2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%

Top News Decliners

8/2 BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq -64.3%

8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%

7/23 Form S-1/A BioCardia, Inc. -14.6%

10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%

9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%

9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%

4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%

8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%

5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%

3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day